Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
66°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tourmaline Bio, Inc. - Common Stock
(NQ:
TRML
)
15.41
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
15.41
Bid (Size)
6.170 (2)
Ask (Size)
20.00 (1)
Prev. Close
15.41
Today's Range
15.41 - 15.41
52wk Range
9.180 - 48.31
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Performance
YTD
-41.85%
-41.85%
1 Month
+4.83%
+4.83%
3 Month
-0.58%
-0.58%
6 Month
-55.42%
-55.42%
1 Year
+41.38%
+41.38%
More News
Read More
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
March 19, 2024
Via
InvestorPlace
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
March 21, 2024
Via
Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Via
Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
March 21, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 29, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
January 25, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
Tourmaline Bio Announces Proposed Public Offering of Common Stock
January 24, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
January 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
January 03, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Via
MarketBeat
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Via
Benzinga
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tourmaline Bio added to the NASDAQ Biotechnology Index
December 15, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
December 14, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
